Skip to content

Emotion and Attention in Alzheimer's Disease (ATEMMA)

Attentional Capture by Emotional Information in Alzheimer's Disease : an fMRI Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03971994
Acronym
ATEMMA
Enrollment
41
Registered
2019-06-03
Start date
2019-05-31
Completion date
2021-11-30
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

attention, emotion, eye movements, amygdala

Brief summary

The main purpose of this study is to investigate the existence of emotional attention impairments in Alzheimer's Disease, in correlation with amygdala and attention networks alterations. To this end, functional and structural neuroimaging will be used. A face expression recognition task, along with eyetracking, will be used to assess emotional attention impairments.

Interventions

BEHAVIORALFacial expression recognition task

We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers : * Affiliation to social security * Medical examination before study participation * No contraindication to MRI * Informed consent signed * Young adults older than 18 years and younger than 40 years * Healthy old adults older than 65 years and younger than 95 years * Visual acuity allowing normal perception of stimuli or corrected to normal vision * Patients with Alzheimer's Disease : * Affiliation to social security * Medical examination before study participation * No contraindication to MRI * Informed consent signed * Patients with Alzheimer's Disease at mild or moderate stage (National Institute on Aging and Alzheimer's Association criteria), diagnosed at Grenoble CMRR (Centre Mémoire de Ressources et de Recherche) * Patients older than 65 years and younger than 95 years * MMSE (Mini-Mental State Examination) \> 18/30 * Ability to understand study instructions and give an informed consent * Visual acuity allowing normal perception of stimuli or corrected to normal vision

Exclusion criteria

* Every participant having a vascular stent implanted less than 6 weeks before study * Every participant having a biomedical material implanted that is considered unsafe in the list: http://www.mrisafety.com/TheList\_search.asp * Every acquisition procedure not respecting required conditions by the conditional usage in a participant having a biomedical material implanted that is considered conditional in the list: http://www.mrisafety.com/TheList\_search.asp * Every subject having a biomedical material such as a cardiac, neuronal or sensorial stimulator (cochlear implant because of demagnetization, electrode heating or artefact risk) or a ventricular drain without trained medical or paramedical support during MRI for these participants * Ferromagnetic object inside the eye or the skull, close to nervous structures (displacement and complications risk such as eye or brain damage) * Claustrophobia * Psychiatric (e.g., bipolar disorder) or neurological pathology (e.g., epilepsy, Parkinson's Disease) other than Alzheimer's Disease * Non cooperating participant * Severe and uncontrolled affection: cardiac, respiratory, haematological, renal, hepatic, cancerous * Participation to other research protocols with exclusion period or MRI during the past weel * Drug therapy likely to modulate brain activity : neuroleptics, lithium, etc... * Alcohol ingestion before study * Participants concerned by articles L1125-5 to L1121-8 of CSP (Code de la Santé Publique) (pregnant or nursing women, underage or protected adult, person under administrative or judicial oversight * Participant receiving more than 4500 euros for his participation to other studies involving human person during the past 12 months before this study * Participant unable to be contacted in case of emergency * Inability to understand study instructions or give an informed consent

Design outcomes

Primary

MeasureTime frameDescription
Classic recognition score1 hourFacial expression recognition score (%)
Classic fixation time faces1 hourFixation time on eyes as measured with eyetracking (ms)
Fixation time scenes30 mnFixation time on emotional scenes outside of MRI
Classic fMRI activity2 hoursfMRI activity in amygdala and emotional attention networks during face exploration and resting-state

Secondary

MeasureTime frameDescription
Alternative fixation time faces1 hourFixation time on eyes as measured with eyetracking (ms) during this alternative task.
Alternative fMRI activity2 hoursfMRI activity in amygdala and emotional attention networks during this alternative task
Alternative recognition score1 hourFacial expression recognition score (%) during an alternative task designed to encourage focus on the eyes

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026